What’s Michael Lytton’s mailing address?
Michael’s mailing address filed with the SEC is 14 CAMBRIDGE CENTER, , CAMBRIDGE, MA, 02142.
Insider trading at Biogen
Over the last 16 years, insiders at Biogen have traded over $156,919,925 worth of Biogen stock and bought 660,866 units worth $181,912,701 . The most active insider traders include Alexander J Denner, Stelios Papadopoulos, and George A Scangos. On average, Biogen executives and independent directors trade stock every 9 days with the average trade being worth of $3,890,229. The most recent stock trade was executed by Ginger Gregory on 1 August 2019, trading 179 units of BIIB stock currently worth $51,731.
What does Biogen do?
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
What does Biogen’s logo look like?
Biogen executives and stock owners
Biogen executives and other stock owners filed with the SEC include:
- Michel Vounatsos, Chief Executive Officer, Director
- Alfred Sandrock, Executive Vice President, Chief Medical Officer
- Michael Ehlers, Executive Vice President, Research and Development
- Susan Alexander, Executive Vice President, Chief Legal Officer and Secretary
- Jeffrey Capello, Chief Financial Officer, Executive Vice President
- Stelios Papadopoulos, Independent Chairman of the Board
- Robert Pangia, Independent Director
- Brian Posner, Independent Director
- Lynn Schenk, Independent Director
- Stephen Sherwin, Independent Director
- Alexander Denner, Independent Director
- Caroline Dorsa, Independent Director
- Eric Rowinsky, Independent Director
- Richard Mulligan, Independent Director
- Nancy Leaming, Independent Director
- Jesus Mantas, Director
- William Hawkins, Director
- John Chiminski, Director
- Robin Kramer, Chief Accounting Officer, Vice President
- Daniel Karp, Executive Vice President, Corporate Development
- Chirfi Guindo, Executive Vice President, Head of Global Marketing, Market Access and Customer Innovation
- Ginger Gregory, Chief Human Resource Officer, Executive Vice President
- George A Scangos, Chief Executive Officer
- Adriana Karaboutis, EVP, Tech. and Bus. Solutions
- Gregory F Covino, VP, Chief Accounting Officer
- Paul Mc Kenzie, EVP Pharmaceutical Oper & Tech
- Paul J Clancy, CFO
- Kenneth Di Pietro, EVP Human Resources
- Adam Koppel, SVP, Chief Strategy Officer
- Jean Paul Kress, EVP Pres Int’l & Global Hd GTO
- Phillip A Sharp, Director
- Steven H Holtzman, EVP Corp Devel and Strategy
- John Cox, EVP Pharmaceutical Oper & Tech
- Spyridon Artavanis Tsakonas, SVP, Chief Scientific Officer
- William Young, Director
- Raymond Pawlicki, SVP, Chief Information Officer
- Stuart A Kingsley, EVP, Global Comm. Operations
- Douglas E Williams, EVP Research & Development
- Craig Eric Schneier, EVP, Human Resources
- Robert E. Gagnon, Chief Acct Officer VP & Contr
- Francesco Granata, EVP Global Commercial Operatio
- James C Mullen, CEO and President
- Michael F Mac Lean, SVP, Chief Accounting Officer
- Bruce Ross, Director
- Robert A Hamm, SVP, Immunology Business Unit
- Cecil B Pickett, President, R & D
- Marijn E Dekkers, Director
- Lawrence C Best, Director
- Faheem Hasnain, SVP, Oncology SBU
- Hans Peter Hasler, SVP, International
- Mark C Wiggins, EVP – Business Development
- Michael Lytton, EVP Corporate & Business Devel
- Alan Glassberg, Director
- John Michael Dunn, EVP – New Ventures
- Michael Gilman, EVP – Research
- Thomas J Bucknum, EVP. General Counsel, Sec.
- Nabil Hanna, EVP, Research
- William H Rastetter, Executive Chairman
- William R Rohn, Exec VP & COO
- Sylvie L Gregoire, EVP, Bus. Dev & Program Mgmt.
- Burt A Adelman, EVP, Development
- Alan Belzer, Director
- Michael Kowolenko, SVP, Pharm Ops & Technology
- Peter N Kellogg, Executive Vice President, CFO
- Mary L Good, Director
- Thomas F Keller, Director
- Connie Matsui, Sr V P, Planning& Resource Dev







